Targeting Cancer with 5 key spotlight sessions on the latest therapy breakthroughs
Posted: 21 July 2016 | SMi Group | No comments yet
SMi’s 5th annual Cancer Vaccines event will showcase 5 key spotlight sessions on the latest advances in vaccine development and cancer therapy breakthroughs when it returns to Central London this autumn…
SMi’s 5th annual Cancer Vaccines event will showcase 5 key spotlight sessions on the latest advances in vaccine development and cancer therapy breakthroughs when it returns to Central London this autumn.
- Vaccine Design and Formulation
Highlights will include two case studies presented by Cancer Research UK on biomarker strategies; and ImmunoCellular Therapeutics on dendritic cell immunotherapy.
- Cancer Immunotherapy
With a focus on immunotherapy in cancer, Abzena’s Senior VP of Scientific Operations will provide progressive insight into product design and in vitro assessment. This will be followed by a presentation from Northwest Biotherapeutic’s CEO, who will give an update on new developments with novel personalised immune therapies.
- Innovations in Vaccine Development
How critical are logistic issues? How can vaccines pass phase 3 trials? Where are the main pitfalls and can these be overcome? These will be just some of the questions answered by Dandrit DanDrit Biotech A/S.
The session will also include presentations on new clinical trial and proof of concept studies with RNA based vaccines from Biontech RNA Pharmaceuticals; peptide based cancer therapy with an academic overview from Nottingham Trent University; and T cell epitope identification with further insight into checkpoint blockade immune characterisation assays from Prolmmune.
- Immune Check Point Inhibitors
Emphasising on omics and big data, Agenus take the next step in combining checkpoint modulators with patient specific vaccines for patient optimised treatment.
MSD go onto explain PD-1 Blockade, a broad spectrum anticancer therapy. Optimise your immune-oncology treatment with strategic guidance on precision medicine, primary resistance and treatment failure.
- Novel Cancer Immunotherapies
GU Malignancies have become an ideal platform for cancer immunotherapy development. Genentech give further insight into combination therapy, disease progression, and identify potential resistance mechanisms through gene expression profiling of responders and non-responders.
A detailed agenda and speaker line-up is available at www.cancervaccinesevent.com
Cancer Vaccines 2016
5th Annual Conference: 21st & 22nd Sept | Interactive Workshop: 20th Sept
Holiday Inn Kensington Forum, London, UK
Proudly Sponsored by: Abzena and Northwest Biotherapeutics
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: [email protected]
To register for the conference, visit www.cancervaccinesevent.com or contact Matthew Apps on
Tel: +44 (0)20 7827 6093 / Email: [email protected]
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
Email: [email protected]